Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency.

Lahman, Miranda C et al.·Science translational medicine·2022·
RPEP-062832022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

The new TCR (TTCR37-45) effectively killed relapsed AML cells resistant to previous targeting.

Key Numbers

How They Did This

The study involved analyzing patient samples and testing T cell receptors in vitro and in a mouse model.

Why This Research Matters

Understanding how leukemia cells evade immune targeting can lead to more effective therapies. This research opens new avenues for treating resistant forms of leukemia.

What This Study Doesn't Tell Us

The study primarily focuses on a small number of patients and in vitro models, which may limit generalizability.

Trust & Context

Original Title:
Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency.
Published In:
Science translational medicine, 14(631), eabg8070 (2022)
Database ID:
RPEP-06283

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-06283·https://rethinkpeptides.com/research/RPEP-06283

APA

Lahman, Miranda C; Schmitt, Thomas M; Paulson, Kelly G; Vigneron, Nathalie; Buenrostro, Denise; Wagener, Felecia D; Voillet, Valentin; Martin, Lauren; Gottardo, Raphael; Bielas, Jason; McElrath, Julie M; Stirewalt, Derek L; Pogosova-Agadjanyan, Era L; Yeung, Cecilia C; Pierce, Robert H; Egan, Daniel N; Bar, Merav; Hendrie, Paul C; Kinsella, Sinéad; Vakil, Aesha; Butler, Jonah; Chaffee, Mary; Linton, Jonathan; McAfee, Megan S; Hunter, Daniel S; Bleakley, Marie; Rongvaux, Anthony; Van den Eynde, Benoit J; Chapuis, Aude G; Greenberg, Philip D. (2022). Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency.. Science translational medicine, 14(631), eabg8070. https://doi.org/10.1126/scitranslmed.abg8070

MLA

Lahman, Miranda C, et al. "Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency.." Science translational medicine, 2022. https://doi.org/10.1126/scitranslmed.abg8070

RethinkPeptides

RethinkPeptides Research Database. "Targeting an alternate Wilms' tumor antigen 1 peptide bypass..." RPEP-06283. Retrieved from https://rethinkpeptides.com/research/lahman-2022-targeting-an-alternate-wilms

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.